vs
Forestar Group Inc.（FOR）与ICU MEDICAL INC（ICUI）财务数据对比。点击上方公司名可切换其他公司
ICU MEDICAL INC的季度营收约是Forestar Group Inc.的2.0倍（$540.7M vs $273.0M），Forestar Group Inc.净利率更高（5.6% vs -2.9%，领先8.6%），Forestar Group Inc.同比增速更快（9.0% vs -14.1%），ICU MEDICAL INC自由现金流更多（$36.0M vs $-157.1M），过去两年ICU MEDICAL INC的营收复合增速更高（-2.3% vs -9.6%）
福雷斯特集团是一家住宅地块开发企业，总部位于得克萨斯州阿灵顿，业务覆盖美国21个州的51个市场。截至2020年12月31日的12个月内，该公司交付了11518块住宅地块，目前在纽约证券交易所上市，自2002年起就是美国规模最大的住宅建筑商D.R. Horton的控股子公司。
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
FOR vs ICUI — 直观对比
营收规模更大
ICUI
是对方的2.0倍
$273.0M
营收增速更快
FOR
高出23.2%
-14.1%
净利率更高
FOR
高出8.6%
-2.9%
自由现金流更多
ICUI
多$193.1M
$-157.1M
两年增速更快
ICUI
近两年复合增速
-9.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $273.0M | $540.7M |
| 净利润 | $15.4M | $-15.7M |
| 毛利率 | 20.1% | 37.5% |
| 营业利润率 | 7.6% | 1.0% |
| 净利率 | 5.6% | -2.9% |
| 营收同比 | 9.0% | -14.1% |
| 净利润同比 | -6.7% | 34.0% |
| 每股收益（稀释后） | $0.30 | $-0.63 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FORICUI
| Q4 25 | $273.0M | $540.7M | ||
| Q3 25 | $670.5M | $537.0M | ||
| Q2 25 | $390.5M | $548.9M | ||
| Q1 25 | $351.0M | $604.7M | ||
| Q4 24 | $250.4M | $629.8M | ||
| Q3 24 | $551.3M | $589.1M | ||
| Q2 24 | $318.4M | $596.5M | ||
| Q1 24 | $333.8M | $566.7M |
净利润FORICUI
| Q4 25 | $15.4M | $-15.7M | ||
| Q3 25 | $86.9M | $-3.4M | ||
| Q2 25 | $32.9M | $35.3M | ||
| Q1 25 | $31.6M | $-15.5M | ||
| Q4 24 | $16.5M | $-23.8M | ||
| Q3 24 | $81.5M | $-33.0M | ||
| Q2 24 | $38.7M | $-21.4M | ||
| Q1 24 | $45.0M | $-39.5M |
毛利率FORICUI
| Q4 25 | 20.1% | 37.5% | ||
| Q3 25 | 22.3% | 37.4% | ||
| Q2 25 | 20.4% | 37.9% | ||
| Q1 25 | 22.6% | 34.7% | ||
| Q4 24 | 22.0% | 36.1% | ||
| Q3 24 | 23.9% | 34.8% | ||
| Q2 24 | 22.5% | 34.8% | ||
| Q1 24 | 24.9% | 32.7% |
营业利润率FORICUI
| Q4 25 | 7.6% | 1.0% | ||
| Q3 25 | 16.9% | 2.6% | ||
| Q2 25 | 11.2% | 1.9% | ||
| Q1 25 | 11.6% | 2.1% | ||
| Q4 24 | 8.7% | 6.0% | ||
| Q3 24 | 19.7% | 1.4% | ||
| Q2 24 | 16.2% | 1.3% | ||
| Q1 24 | 17.6% | -1.9% |
净利率FORICUI
| Q4 25 | 5.6% | -2.9% | ||
| Q3 25 | 13.0% | -0.6% | ||
| Q2 25 | 8.4% | 6.4% | ||
| Q1 25 | 9.0% | -2.6% | ||
| Q4 24 | 6.6% | -3.8% | ||
| Q3 24 | 14.8% | -5.6% | ||
| Q2 24 | 12.2% | -3.6% | ||
| Q1 24 | 13.5% | -7.0% |
每股收益（稀释后）FORICUI
| Q4 25 | $0.30 | $-0.63 | ||
| Q3 25 | $1.70 | $-0.14 | ||
| Q2 25 | $0.65 | $1.43 | ||
| Q1 25 | $0.62 | $-0.63 | ||
| Q4 24 | $0.32 | $-0.97 | ||
| Q3 24 | $1.59 | $-1.35 | ||
| Q2 24 | $0.76 | $-0.88 | ||
| Q1 24 | $0.89 | $-1.63 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $211.7M | — |
| 总债务越低越好 | $793.2M | — |
| 股东权益账面价值 | $1.8B | $2.1B |
| 总资产 | $3.2B | $4.1B |
| 负债/权益比越低杠杆越低 | 0.44× | — |
8季度趋势，按日历期对齐
现金及短期投资FORICUI
| Q4 25 | $211.7M | — | ||
| Q3 25 | $379.2M | — | ||
| Q2 25 | $189.2M | — | ||
| Q1 25 | $174.3M | — | ||
| Q4 24 | $132.0M | $308.6M | ||
| Q3 24 | $481.2M | $312.5M | ||
| Q2 24 | $359.2M | $302.6M | ||
| Q1 24 | $416.2M | $251.4M |
总债务FORICUI
| Q4 25 | $793.2M | — | ||
| Q3 25 | $802.7M | — | ||
| Q2 25 | $872.8M | — | ||
| Q1 25 | $872.5M | — | ||
| Q4 24 | $806.8M | — | ||
| Q3 24 | $706.4M | — | ||
| Q2 24 | $706.1M | — | ||
| Q1 24 | $705.7M | — |
股东权益FORICUI
| Q4 25 | $1.8B | $2.1B | ||
| Q3 25 | $1.8B | $2.1B | ||
| Q2 25 | $1.7B | $2.1B | ||
| Q1 25 | $1.6B | $2.0B | ||
| Q4 24 | $1.6B | $2.0B | ||
| Q3 24 | $1.6B | $2.0B | ||
| Q2 24 | $1.5B | $2.0B | ||
| Q1 24 | $1.5B | $2.1B |
总资产FORICUI
| Q4 25 | $3.2B | $4.1B | ||
| Q3 25 | $3.1B | $4.1B | ||
| Q2 25 | $3.1B | $4.1B | ||
| Q1 25 | $3.0B | $4.2B | ||
| Q4 24 | $3.0B | $4.2B | ||
| Q3 24 | $2.8B | $4.3B | ||
| Q2 24 | $2.7B | $4.3B | ||
| Q1 24 | $2.6B | $4.3B |
负债/权益比FORICUI
| Q4 25 | 0.44× | — | ||
| Q3 25 | 0.45× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.53× | — | ||
| Q4 24 | 0.50× | — | ||
| Q3 24 | 0.44× | — | ||
| Q2 24 | 0.47× | — | ||
| Q1 24 | 0.48× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-157.0M | $60.6M |
| 自由现金流经营现金流 - 资本支出 | $-157.1M | $36.0M |
| 自由现金流率自由现金流/营收 | -57.5% | 6.6% |
| 资本支出强度资本支出/营收 | 0.0% | 4.6% |
| 现金转化率经营现金流/净利润 | -10.19× | — |
| 过去12个月自由现金流最近4个季度 | $93.0M | $91.8M |
8季度趋势，按日历期对齐
经营现金流FORICUI
| Q4 25 | $-157.0M | $60.6M | ||
| Q3 25 | $256.3M | $56.7M | ||
| Q2 25 | $15.8M | $11.2M | ||
| Q1 25 | $-19.8M | $51.3M | ||
| Q4 24 | $-450.0M | $40.2M | ||
| Q3 24 | $119.2M | $36.1M | ||
| Q2 24 | $-61.7M | $82.0M | ||
| Q1 24 | $-59.2M | $45.8M |
自由现金流FORICUI
| Q4 25 | $-157.1M | $36.0M | ||
| Q3 25 | $255.6M | $27.6M | ||
| Q2 25 | $15.0M | $-8.5M | ||
| Q1 25 | $-20.5M | $36.7M | ||
| Q4 24 | — | $16.1M | ||
| Q3 24 | $118.4M | $16.2M | ||
| Q2 24 | $-62.3M | $62.5M | ||
| Q1 24 | $-59.8M | $29.9M |
自由现金流率FORICUI
| Q4 25 | -57.5% | 6.6% | ||
| Q3 25 | 38.1% | 5.1% | ||
| Q2 25 | 3.8% | -1.5% | ||
| Q1 25 | -5.8% | 6.1% | ||
| Q4 24 | — | 2.6% | ||
| Q3 24 | 21.5% | 2.7% | ||
| Q2 24 | -19.6% | 10.5% | ||
| Q1 24 | -17.9% | 5.3% |
资本支出强度FORICUI
| Q4 25 | 0.0% | 4.6% | ||
| Q3 25 | 0.1% | 5.4% | ||
| Q2 25 | 0.2% | 3.6% | ||
| Q1 25 | 0.2% | 2.4% | ||
| Q4 24 | 0.0% | 3.8% | ||
| Q3 24 | 0.1% | 3.4% | ||
| Q2 24 | 0.2% | 3.3% | ||
| Q1 24 | 0.2% | 2.8% |
现金转化率FORICUI
| Q4 25 | -10.19× | — | ||
| Q3 25 | 2.95× | — | ||
| Q2 25 | 0.48× | 0.32× | ||
| Q1 25 | -0.63× | — | ||
| Q4 24 | -27.27× | — | ||
| Q3 24 | 1.46× | — | ||
| Q2 24 | -1.59× | — | ||
| Q1 24 | -1.32× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FOR
| D.R.Horton Inc. | $183.8M | 67% |
| Other | $89.2M | 33% |
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
